These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 23765441)
21. Blood and cerebellar abundance of ATXN3 splice variants in spinocerebellar ataxia type 3/Machado-Joseph disease. Raposo M; Hübener-Schmid J; Tagett R; Ferreira AF; Vieira Melo AR; Vasconcelos J; Pires P; Kay T; Garcia-Moreno H; Giunti P; Santana MM; Pereira de Almeida L; Infante J; van de Warrenburg BP; de Vries JJ; Faber J; Klockgether T; Casadei N; Admard J; Schöls L; Riess O; ; Costa MDC; Lima M Neurobiol Dis; 2024 Apr; 193():106456. PubMed ID: 38423193 [TBL] [Abstract][Full Text] [Related]
22. RNA Interference Therapy for Machado-Joseph Disease: Long-Term Safety Profile of Lentiviral Vectors Encoding Short Hairpin RNAs Targeting Mutant Ataxin-3. Nóbrega C; Codêsso JM; Mendonça L; Pereira de Almeida L Hum Gene Ther; 2019 Jul; 30(7):841-854. PubMed ID: 30760052 [TBL] [Abstract][Full Text] [Related]
23. Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease. Gonçalves N; Simões AT; Cunha RA; de Almeida LP Ann Neurol; 2013 May; 73(5):655-66. PubMed ID: 23625556 [TBL] [Abstract][Full Text] [Related]
24. Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease. Silva-Fernandes A; Duarte-Silva S; Neves-Carvalho A; Amorim M; Soares-Cunha C; Oliveira P; Thirstrup K; Teixeira-Castro A; Maciel P Neurotherapeutics; 2014 Apr; 11(2):433-49. PubMed ID: 24477711 [TBL] [Abstract][Full Text] [Related]
25. Overexpression of mutant ataxin-3 in mouse cerebellum induces ataxia and cerebellar neuropathology. Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Conceição M; Déglon N; de Almeida LP Cerebellum; 2013 Aug; 12(4):441-55. PubMed ID: 23242710 [TBL] [Abstract][Full Text] [Related]
26. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease. Matos CA; de Macedo-Ribeiro S; Carvalho AL Prog Neurobiol; 2011 Sep; 95(1):26-48. PubMed ID: 21740957 [TBL] [Abstract][Full Text] [Related]
27. Pharmacological enhancement of retinoid-related orphan receptor α function mitigates spinocerebellar ataxia type 3 pathology. Watanave M; Hoshino C; Konno A; Fukuzaki Y; Matsuzaki Y; Ishitani T; Hirai H Neurobiol Dis; 2019 Jan; 121():263-273. PubMed ID: 30343032 [TBL] [Abstract][Full Text] [Related]
28. Lithium chloride therapy fails to improve motor function in a transgenic mouse model of Machado-Joseph disease. Duarte-Silva S; Neves-Carvalho A; Soares-Cunha C; Teixeira-Castro A; Oliveira P; Silva-Fernandes A; Maciel P Cerebellum; 2014 Dec; 13(6):713-27. PubMed ID: 25112410 [TBL] [Abstract][Full Text] [Related]
29. Caloric restriction blocks neuropathology and motor deficits in Machado-Joseph disease mouse models through SIRT1 pathway. Cunha-Santos J; Duarte-Neves J; Carmona V; Guarente L; Pereira de Almeida L; Cavadas C Nat Commun; 2016 May; 7():11445. PubMed ID: 27165717 [TBL] [Abstract][Full Text] [Related]
30. The role of apolipoprotein E as a risk factor for an earlier age at onset for Machado-Joseph disease is doubtful. Zhou Q; Ni W; Dong Y; Wang N; Gan SR; Wu ZY PLoS One; 2014; 9(11):e111356. PubMed ID: 25369462 [TBL] [Abstract][Full Text] [Related]
31. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. Goti D; Katzen SM; Mez J; Kurtis N; Kiluk J; Ben-Haïem L; Jenkins NA; Copeland NG; Kakizuka A; Sharp AH; Ross CA; Mouton PR; Colomer V J Neurosci; 2004 Nov; 24(45):10266-79. PubMed ID: 15537899 [TBL] [Abstract][Full Text] [Related]
32. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis. Williams AJ; Knutson TM; Colomer Gould VF; Paulson HL Neurobiol Dis; 2009 Mar; 33(3):342-53. PubMed ID: 19084066 [TBL] [Abstract][Full Text] [Related]
33. The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability. Durcan TM; Kontogiannea M; Thorarinsdottir T; Fallon L; Williams AJ; Djarmati A; Fantaneanu T; Paulson HL; Fon EA Hum Mol Genet; 2011 Jan; 20(1):141-54. PubMed ID: 20940148 [TBL] [Abstract][Full Text] [Related]
34. RNA interference mitigates motor and neuropathological deficits in a cerebellar mouse model of Machado-Joseph disease. Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Déglon N; de Almeida LP PLoS One; 2014; 9(8):e100086. PubMed ID: 25144231 [TBL] [Abstract][Full Text] [Related]
35. Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice. McLoughlin HS; Moore LR; Chopra R; Komlo R; McKenzie M; Blumenstein KG; Zhao H; Kordasiewicz HB; Shakkottai VG; Paulson HL Ann Neurol; 2018 Jul; 84(1):64-77. PubMed ID: 29908063 [TBL] [Abstract][Full Text] [Related]
36. Does DNA methylation in the promoter region of the ATXN3 gene modify age at onset in MJD (SCA3) patients? Emmel VE; Alonso I; Jardim LB; Saraiva-Pereira ML; Sequeiros J Clin Genet; 2011 Jan; 79(1):100-2. PubMed ID: 21143471 [No Abstract] [Full Text] [Related]
37. Polyglutamine-expanded ataxin-3 impairs long-term depression in Purkinje neurons of SCA3 transgenic mouse by inhibiting HAT and impairing histone acetylation. Chou AH; Chen YL; Hu SH; Chang YM; Wang HL Brain Res; 2014 Oct; 1583():220-9. PubMed ID: 25139423 [TBL] [Abstract][Full Text] [Related]
38. ULK overexpression mitigates motor deficits and neuropathology in mouse models of Machado-Joseph disease. Vasconcelos-Ferreira A; Martins IM; Lobo D; Pereira D; Lopes MM; Faro R; Lopes SM; Verbeek D; Schmidt T; Nóbrega C; Pereira de Almeida L Mol Ther; 2022 Jan; 30(1):370-387. PubMed ID: 34298131 [TBL] [Abstract][Full Text] [Related]
39. Calpain inhibition reduces ataxin-3 cleavage alleviating neuropathology and motor impairments in mouse models of Machado-Joseph disease. Simões AT; Gonçalves N; Nobre RJ; Duarte CB; Pereira de Almeida L Hum Mol Genet; 2014 Sep; 23(18):4932-44. PubMed ID: 24817574 [TBL] [Abstract][Full Text] [Related]
40. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]